For a few weeks in January, Valeant Pharmaceuticals‘ (NYSE: VRX) stock outperformed the S&P 500 index. The run didn’t last long, though. Here’s why Valeant’s rebound quickly fizzled.
The first phase of Valeant’s failed rebound started with the stock’s collapse. And did it ever collapse. Valeant has lost over 94% of its market cap since August 2015.